CoChat

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Abstract

Background/aim Ursodeoxycholic acid in doses of 13-15 mg x kg(-1) x day(-1), is a safe and cost-effective treatment for patients with primary biliary cirrhosis. However, very limited information exists regarding the most appropriate dose of ursodeoxycholic acid. The aim of the study was to compare three dosages of ursodeoxycholic acid with respect to changes in liver biochemistries, Mayo risk score, biliary enrichment with ursodeoxycholic acid and side effects over at least a 1-year period. Methods A total of 155 patients were randomized to receive low- (5-7 mg x kg(-1) x day(-1)), standard-(13-15 mg x kg(-1) x day(-1)), and high- (23-25 mg x kg(-1) x day(-1)) doses of ursodeoxycholic acid. Results The improvements in alkaline phosphatase (p = 0.0001), aspartate aminotransferase (p = 0.0001), Mayo risk score (p = 0.002), and ursodeoxycholic acid enrichment (p = 0.0001) were significantly greater in the standard- and high-dose groups compared to the low-dose group, but not between the standard- and high-dose groups. Changes in serum bilirubin were similar between the three groups (p = 0.07). No significant effects on symptoms were noted with any dose. No patients discontinued ursodeoxycholic acid because of side effects or toxicity. Conclusions Ursodeoxycholic acid in doses of 5-25 mg x kg(-1) x day(-1) is safe and well tolerated. The dose of 13-15 mg x kg(-1) x day(-1) appears to be the preferred dose for patients with primary biliary cirrhosis.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0168-8278(99)80136-6

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 4

  1. Lacerda, 1993, Ursodiol therapy in primary biliary cirrhosis (PBC): enrichment correlates with biochemical improvement, Gastroenterology, 104, A933
  2. Pasha, 1996, Early predictors of treatment failure in patients treated with ursodeoxycholic acid for primary biliary cirrhosis, Gastroenterology, 110, A129
  3. Poupon, 1997, Prognostic factors in ursodeoxycholic acid treated patients with primary biliary cirrhosis, Hepatology, 26, 400A
  4. Emond, 1996, Does ursodeoxycholic acid improve survival in patients with primary biliary cirrhosis? Comparison of outcome in the U.S. multicenter trial to expected survival using the Mayo Clinic prognostic model, Hepatology, 24, 168A

Cited by

See all 134

Metadata

Authors
Angulo, P., Dickson, E. R., Therneau, T. M., Jorgensen, R. A., Smith, C., DeSotel, C. K., Lange, S. M., Anderson, M. L., Mahoney, D. W., & Lindor, K. D.
Affiliations
  • Mayo Clinic (US)
  • MNGI Digestive Health (US)
  • Mayo Clinic in Arizona (US)
Corresponding author
Lindor, Keith D
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
1999-05
Volume
30
Issue
5
Pages
830-835
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2058378324
Cited by
134
References
25
Citations by year
2026: 2 · 2025: 6 · 2024: 4 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 8 · 2016: 3 · 2015: 5 · 2014: 7 · 2013: 4 · 2012: 7
FWCI
4.06
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
ursodeoxycholic acid, primary biliary cirrhosis, dose comparison, dose-response relationship, liver biochemistry, Mayo risk score, adverse drug reactions, alkaline phosphatase, aspartate aminotransferase, serum bilirubin
MeSH terms
Alkaline Phosphatase, Aspartate Aminotransferases, Bilirubin, Cholagogues and Choleretics, Dose-Response Relationship, Drug, Female, Humans, Liver, Liver Cirrhosis, Biliary, Male, Middle Aged, Time Factors, Ursodeoxycholic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. https://app.cochat.ai/papers/10.1016/s0168-8278(99)80136-6
The paper
Angulo, P., Dickson, E. R., Therneau, T. M., Jorgensen, R. A., Smith, C., DeSotel, C. K., Lange, S. M., Anderson, M. L., Mahoney, D. W., & Lindor, K. D. (1999). Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(99)80136-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.